Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document the biotechnology company's acellular tissue platform, listed redeemable warrants and material corporate events. Form 8-K reports cover Nasdaq listing-compliance notices and amendments to distribution arrangements for the 6 millimeter acellular tissue engineered vessel-tyod, including worldwide development, commercialization and regulatory rights. Proxy materials cover board and shareholder voting matters, executive compensation, equity awards and governance. The filing record also identifies HUMAW as redeemable warrants, each whole warrant exercisable for one share of common stock at $11.50, traded on Nasdaq.
Humacyte, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common shares from 350,000,000 to 550,000,000, which became effective upon filing in Delaware on June 9, 2026.
As of the April 23, 2026 record date, 222,019,108 common shares were outstanding, and 127,474,086 shares, or about 57.41%, were represented to form a quorum. Stockholders elected three Class II directors, approved on an advisory basis the compensation of named executive officers and chose to hold future say-on-pay votes annually.
They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and formally approved the increase in authorized common stock. No broker non-votes were recorded on the auditor ratification or share authorization proposals.
Humacyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company had previously been notified that its common stock traded below the required $1.00 per share bid price for 30 consecutive business days ended May 1, 2026.
To cure the issue, Humacyte’s stock needed to close at or above $1.00 for at least 10 consecutive business days before November 2, 2026. On June 5, 2026, Nasdaq informed the company that this condition was met and that its listing on The Nasdaq Global Select Market is now in good standing, with the matter considered closed.
Humacyte, Inc. director Kathleen Sebelius reported an open-market purchase of 56,818 shares of Humacyte common stock at a price of $0.88 per share on May 19, 2026. Following this transaction, she directly holds a total of 148,025 Humacyte common shares.
Humacyte, Inc. director Michael T. Constantino reported an open-market purchase of common stock. On May 18, 2026, he bought 11,000 shares of Humacyte common stock at a weighted average price of $0.8945 per share in multiple transactions.
Following this purchase, Constantino directly owns 43,950 common shares. The filing notes that the trades were executed across a price range from $0.8922 to $0.8958 per share and that detailed trade-by-trade pricing is available upon request.
Humacyte, Inc. CFO and Chief Corporate Development Officer Dale A. Sander reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share. The sale was executed solely to cover statutory tax withholding from vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan, not as a discretionary sale. After this transaction, he holds 267,213 shares directly and 40,600 shares indirectly through his spouse.
Humacyte, Inc.'s Chief Medical Officer, Shamik J. Parikh, reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share.
The filing explains this was a mandatory “sell-to-cover” transaction to fund statutory tax withholding tied to vesting of restricted stock units, carried out under a Rule 10b5-1(c) trading plan and not a discretionary sale. After this tax-related sale, Parikh directly holds 272,713 shares of Humacyte common stock.
Humacyte, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, compared with net income of $39.1 million a year earlier, as favorable fair value movements on earnout and warrant liabilities were much smaller than in 2025.
Total revenue was $0.5 million, with product revenue from Symvess increasing to $493,000 while contract revenue declined. Operating expenses rose to $29.4 million, driven mainly by higher research and development spending of $19.5 million.
Humacyte used $25.1 million of cash in operating activities and ended the quarter with cash and cash equivalents of $48.5 million. Management states that these resources are not sufficient to fund operations beyond one year without stronger Symvess sales and/or additional financing, raising substantial doubt about the company’s ability to continue as a going concern.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price was below the required $1.00 per share for 30 consecutive business days ended May 1, 2026, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1).
The company has 180 calendar days, until November 2, 2026, for its closing bid price to be at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance. Trading of the stock and the company’s operations and SEC reporting continue unchanged for now, but there is explicit delisting risk if compliance is not restored.